Detalles de la búsqueda
1.
Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission.
Blood
; 143(5): 417-421, 2024 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37879077
2.
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party.
Blood
; 138(26): 2753-2767, 2021 12 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-34724563
3.
Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results.
Am J Hematol
; 98(3): 493-501, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36600670
4.
Ibrutinib and Venetoclax for First-Line Treatment of CLL.
N Engl J Med
; 380(22): 2095-2103, 2019 05 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-31141631
5.
Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10-4 and higher.
Am J Hematol
; 97(9): 1135-1141, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35713551
6.
Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.
Cancer
; 127(18): 3381-3389, 2021 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34138471
7.
Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
Cancer
; 127(12): 2025-2038, 2021 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33740268
8.
Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia.
Br J Haematol
; 192(6): 1054-1063, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33618432
9.
Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy.
Blood
; 134(22): 1951-1959, 2019 11 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-31537528
10.
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.
Blood
; 133(10): 1011-1019, 2019 03 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30530801
11.
Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm.
Haematologica
; 106(4): 1047-1055, 2021 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32241840
12.
Considering intervention intensity in habitat restoration planning: An application to Pacific salmon.
J Environ Manage
; 299: 113536, 2021 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34526281
13.
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.
Blood
; 131(12): 1275-1291, 2018 03 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-29330221
14.
Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia.
Am J Hematol
; 95(7): 734-739, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32170867
15.
The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival.
Am J Hematol
; 95(2): 144-150, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31682008
16.
Tumor infiltrating lymphocyte grade in Merkel cell carcinoma: relationships with clinical factors and independent prognostic value.
Acta Oncol
; 59(12): 1409-1415, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32687000
17.
Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy.
Br J Haematol
; 186(4): 538-548, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31115909
18.
Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults.
Blood
; 129(5): 572-581, 2017 02 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27919910
19.
Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia.
Haematologica
; 104(2): 305-311, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30171025
20.
CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia.
Haematologica
; 104(4): 749-755, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30361418